67 related articles for article (PubMed ID: 2040933)
1. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.
Shannon KM; Mentzer WC; Abels RI; Freeman P; Newton N; Thompson D; Sniderman S; Ballard R; Phibbs RH
J Pediatr; 1991 Jun; 118(6):949-55. PubMed ID: 2040933
[TBL] [Abstract][Full Text] [Related]
2. A randomized, masked study of weekly erythropoietin dosing in preterm infants.
Ohls RK; Roohi M; Peceny HM; Schrader R; Bierer R
J Pediatr; 2012 May; 160(5):790-5.e1. PubMed ID: 22137666
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: a retrospective single-center cohort study.
Connolly JM; McClary JD; Desai R; Sundaram A; Neudecker M; Nock ML; Ryan RM; Marasch JL
J Perinatol; 2024 Jun; 44(6):892-896. PubMed ID: 38773216
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use.
Perrone S; Lembo C; Gironi F; Petrolini C; Catalucci T; Corbo G; Buonocore G; Gitto E; Esposito SMR
Antioxidants (Basel); 2022 Mar; 11(4):. PubMed ID: 35453337
[TBL] [Abstract][Full Text] [Related]
5. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Aher SM; Ohlsson A
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD004868. PubMed ID: 31990982
[TBL] [Abstract][Full Text] [Related]
6. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
Aher SM; Ohlsson A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD004868. PubMed ID: 30776084
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes Related to the Gastrointestinal Trophic Effects of Erythropoietin in Preterm Neonates: A Systematic Review and Meta-Analysis.
Ananthan A; Balasubramanian H; Rao S; Patole S
Adv Nutr; 2018 May; 9(3):238-246. PubMed ID: 29767696
[TBL] [Abstract][Full Text] [Related]
8. Transfusion support in preterm neonates <1500 g and/or <32 weeks in a tertiary care center: A descriptive study.
Shanmugha Priya RA; Krishnamoorthy R; Panicker VK; Ninan B
Asian J Transfus Sci; 2018; 12(1):34-41. PubMed ID: 29563673
[TBL] [Abstract][Full Text] [Related]
9. The effect of erythropoietin on normal and neoplastic cells.
Elliott S; Sinclair AM
Biologics; 2012; 6():163-89. PubMed ID: 22848149
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.
Neelakantan S; Widness JA; Schmidt RL; Veng-Pedersen P
Pediatr Int; 2009 Feb; 51(1):25-32. PubMed ID: 19371274
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin: when liability becomes asset in neurovascular repair.
Grant MB; Boulton ME; Ljubimov AV
J Clin Invest; 2008 Feb; 118(2):467-70. PubMed ID: 18219388
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the surgical treatment of congenital heart disease in children of Jehovah's Witnesses.
Cooley DA; Burnett CM
Tex Heart Inst J; 1992; 19(3):156-9. PubMed ID: 15227432
[No Abstract] [Full Text] [Related]
13. Does early erythropoietin therapy decrease transfusions in anemia of prematurity?
Atasay B; Günlemez A; Akar N; Arsan S
Indian J Pediatr; 2002 May; 69(5):389-91. PubMed ID: 12061670
[TBL] [Abstract][Full Text] [Related]
14. Anaemia of prematurity. Epidemiology, management and costs.
Meyer MP
Pharmacoeconomics; 1997 Oct; 12(4):438-45. PubMed ID: 10174310
[TBL] [Abstract][Full Text] [Related]
15. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.
Carnielli VP; Da Riol R; Montini G
Arch Dis Child Fetal Neonatal Ed; 1998 Jul; 79(1):F44-8. PubMed ID: 9797624
[TBL] [Abstract][Full Text] [Related]
16. Haemopoietic colony stimulating factors for preterm neonates.
Carr R; Modi N
Arch Dis Child Fetal Neonatal Ed; 1997 Mar; 76(2):F128-33. PubMed ID: 9135294
[No Abstract] [Full Text] [Related]
17. Blood transfusions and human recombinant erythropoietin in premature newborn infants.
Williamson P; Griffiths G; Norfolk D; Levene M
Arch Dis Child Fetal Neonatal Ed; 1996 Jul; 75(1):F65-8. PubMed ID: 8795362
[No Abstract] [Full Text] [Related]
18. Factors related to transfusion in very low birthweight infants treated with erythropoietin.
Maier RF; Obladen M; Messinger D; Wardrop CA
Arch Dis Child Fetal Neonatal Ed; 1996 May; 74(3):F182-6. PubMed ID: 8777681
[TBL] [Abstract][Full Text] [Related]
19. Reducing donor exposure in preterm infants requiring multiple blood transfusions.
Wood A; Wilson N; Skacel P; Thomas R; Tidmarsh E; Yale C; de Silva M
Arch Dis Child Fetal Neonatal Ed; 1995 Jan; 72(1):F29-33. PubMed ID: 7743280
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
Markham A; Bryson HM
Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
